本帖最后由 老马 于 2013-3-13 13:43 编辑
: M& c! T- M; o
" A- D6 U' c% u O4 p健择（吉西他滨）+顺铂+阿瓦斯汀" z5 J; h# K. |8 o8 G9 s
Gemzar +Cisplatin + Avastin8 J* T0 f1 I7 @9 ^/ J% e0 t
http://annonc.oxfordjournals.org/content/21/9/1804.full; n( }# @ i0 M- U @
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' g- \/ P$ A6 u, _- H$ j9 f% GPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
! y8 E- J0 t( h6 yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 5 F0 x! F8 Z. T
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 922)
`. [8 a* Y; u$ ~9 K1 g华为网盘附件：5 a# d5 p% g, z' ^" [
【华为网盘】ava.JPG/ L: h' L, a/ s
|
无靶点 her2扩增 二线白紫耐药后怎么
家父今年62岁，22年11月份颈部淋巴结穿刺，确诊肺低分化腺癌，分期是TxN3M1，基因检测
父亲肺鳞癌，cT3N0M1a，ⅣA，脑转移
父亲2025年6月中旬因为头痛，一侧肢体不灵活入院，做了增强核磁，发现右侧额叶占位（3
120万一针的抗癌药在肿瘤患者体内就
作者：Tony
一提起CAR-T，很多人都会想到的是其120万一针的恐怖价格，它是治愈癌症的
妈妈化疗的艰难时刻，倍瑞博营养液带
当母亲被确诊为肺腺癌四期的那一刻，我们全家如坠冰窟。随之而来的化疗更是煎熬——
惋惜 关于一位术后2期肺腺癌病友止步
曾经一起抗癌的老病友很多都陆陆续续地抗癌结束了，如今都各自有了新的生活，当
显身卡
